IMPORTANCE: Continuous renal replacement therapy (CRRT) benefits patients with renal failure who are too hemodynamically unstable for intermittent hemodialysis. The duration of therapy beyond which continued use is futile, particularly in a population of patients admitted to and primarily cared for by a surgical service (hereinafter referred to as surgical patients), is unclear. OBJECTIVE: To analyze proportions of and independent risk factors for survival to discharge after initiation of CRRT among patients in a surgical intensive care unit (SICU). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included all patients undergoing CRRT from July 1, 2012, through January 31, 2016, in an SICU of an urban tertiary medical center. The population included patients treated before or after general surgery and patients admitted to a surgical service during inpatient evaluation and care before liver transplant. The pretransplant population was censored from further survival analysis on receipt of a transplant. EXPOSURES: Continuous renal replacement therapy. MAIN OUTCOMES AND MEASURES: Hospital mortality among patients in an SICU after initiation of CRRT. RESULTS: Of 108 patients (64 men [59.3%] and 44 women [40.7%]; mean [SD] age, 62.0 [12.7] years) admitted to the SICU, 53 were in the general surgical group and 55 in the pretransplant group. Thirteen of the 22 patients in the pretransplant group who required 7 or more days of CRRT died (in-hospital mortality, 59.1%); among the 12 patients in the general surgery group who required 7 or more days of CRRT, 12 died (in-hospital mortality, 100%). In the general surgical group, each day of CRRT was associated with an increased adjusted odds ratio of death of 1.39 (95% CI, 1.01-1.90; P = .04). CONCLUSIONS AND RELEVANCE: Continuous renal replacement therapy is valuable for surgical patients with an acute and correctable indication; however, survival decreases significantly with increasing duration of CRRT. Duration of CRRT does not correlate with survival among patients awaiting liver transplant.
IMPORTANCE: Continuous renal replacement therapy (CRRT) benefits patients with renal failure who are too hemodynamically unstable for intermittent hemodialysis. The duration of therapy beyond which continued use is futile, particularly in a population of patients admitted to and primarily cared for by a surgical service (hereinafter referred to as surgical patients), is unclear. OBJECTIVE: To analyze proportions of and independent risk factors for survival to discharge after initiation of CRRT among patients in a surgical intensive care unit (SICU). DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included all patients undergoing CRRT from July 1, 2012, through January 31, 2016, in an SICU of an urban tertiary medical center. The population included patients treated before or after general surgery and patients admitted to a surgical service during inpatient evaluation and care before liver transplant. The pretransplant population was censored from further survival analysis on receipt of a transplant. EXPOSURES: Continuous renal replacement therapy. MAIN OUTCOMES AND MEASURES: Hospital mortality among patients in an SICU after initiation of CRRT. RESULTS: Of 108 patients (64 men [59.3%] and 44 women [40.7%]; mean [SD] age, 62.0 [12.7] years) admitted to the SICU, 53 were in the general surgical group and 55 in the pretransplant group. Thirteen of the 22 patients in the pretransplant group who required 7 or more days of CRRT died (in-hospital mortality, 59.1%); among the 12 patients in the general surgery group who required 7 or more days of CRRT, 12 died (in-hospital mortality, 100%). In the general surgical group, each day of CRRT was associated with an increased adjusted odds ratio of death of 1.39 (95% CI, 1.01-1.90; P = .04). CONCLUSIONS AND RELEVANCE: Continuous renal replacement therapy is valuable for surgical patients with an acute and correctable indication; however, survival decreases significantly with increasing duration of CRRT. Duration of CRRT does not correlate with survival among patients awaiting liver transplant.
Authors: Hyung Jung Oh; Min Hyung Kim; Jin Young Ahn; Nam Su Ku; Jung Tak Park; Sang Hoon Han; Jun Yong Choi; Seung Hyeok Han; Tae-Hyun Yoo; Young Goo Song; Shin-Wook Kang; June Myung Kim Journal: J Crit Care Date: 2016-05-04 Impact factor: 3.425
Authors: Laurent Brochard; Fekri Abroug; Matthew Brenner; Alain F Broccard; Robert L Danner; Miquel Ferrer; Franco Laghi; Sheldon Magder; Laurent Papazian; Paolo Pelosi; Kees H Polderman Journal: Am J Respir Crit Care Med Date: 2010-05-15 Impact factor: 21.405
Authors: Eric A J Hoste; Sean M Bagshaw; Rinaldo Bellomo; Cynthia M Cely; Roos Colman; Dinna N Cruz; Kyriakos Edipidis; Lui G Forni; Charles D Gomersall; Deepak Govil; Patrick M Honoré; Olivier Joannes-Boyau; Michael Joannidis; Anna-Maija Korhonen; Athina Lavrentieva; Ravindra L Mehta; Paul Palevsky; Eric Roessler; Claudio Ronco; Shigehiko Uchino; Jorge A Vazquez; Erick Vidal Andrade; Steve Webb; John A Kellum Journal: Intensive Care Med Date: 2015-07-11 Impact factor: 17.440
Authors: Carlos V R Brown; Joseph J Dubose; Pantelis Hadjizacharia; Hakan Yanar; Ali Salim; Kenji Inaba; Peter Rhee; Linda Chan; Demetrios Demetriades Journal: J Am Coll Surg Date: 2007-11-26 Impact factor: 6.113
Authors: Mohammad H Al-Shaer; Kelly Maguigan; Jennifer Ashton; Veena Venugopalan; Molly E Droege; Carolyn D Philpott; Christopher A Droege; Daniel P Healy; Eric W Mueller; Charles A Peloquin Journal: Antimicrob Agents Chemother Date: 2021-10-18 Impact factor: 5.938
Authors: Charat Thongprayoon; Yeshwanter Radhakrishnan; Wisit Cheungpasitporn; Tananchai Petnak; Fawad Qureshi; Michael A Mao; Kianoush B Kashani Journal: Can J Kidney Health Dis Date: 2022-07-26
Authors: Daniel J Selig; Jesse P DeLuca; Kevin K Chung; Kaitlin A Pruskowski; Jeffrey R Livezey; Robert J Nadeau; Elaine D Por; Kevin S Akers Journal: J Clin Pharm Ther Date: 2022-03-29 Impact factor: 2.145